Back to Newsroom

Pivotal Pharmacokinetic Study of Innocoll’s XaraColl(R) Supports Use of 300 mg Dose for Phase 3 Clinical Studies in Post-Operative Pain

ATHLONE, Ireland, April 1, 2015 (GLOBE NEWSWIRE) — Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced that the results of a pharmacokinetic (PK) study support using a dose of 300 mg of XaraColl, Innocoll’s collagen/bupivacaine bioresorbable implant, in its planned Phase 3 studies to evaluate the efficacy of XaraColl in the treatment of post-operative pain.

Click here to read more